EP0666748A1 - The use of inositoltrisphosphate for the preparation of medicaments - Google Patents

The use of inositoltrisphosphate for the preparation of medicaments

Info

Publication number
EP0666748A1
EP0666748A1 EP93924853A EP93924853A EP0666748A1 EP 0666748 A1 EP0666748 A1 EP 0666748A1 EP 93924853 A EP93924853 A EP 93924853A EP 93924853 A EP93924853 A EP 93924853A EP 0666748 A1 EP0666748 A1 EP 0666748A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
hydroxyl
phosphate
pain
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93924853A
Other languages
German (de)
English (en)
French (fr)
Inventor
Matti Siren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perstorp AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Publication of EP0666748A1 publication Critical patent/EP0666748A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to the use of at least one isomer of inositoltrisphosphate (IP 3 ) for the preparing of a medicament effective as an analgesic.
  • IP 3 inositoltrisphosphate
  • Another type of pharmaceuticals used to reduce pain are sedative agents such as barbiturates and benzodiazepines. Many of these drugs have side effects such as depressant action on respiration and circulation and are producing nausea and vomiting, which limit their use to many groups of patients. Furthermore many of the used drugs give hypnotic effects which are undesirable for the patient.
  • Nonsteroidal anti-inflammatory drugs are used to treat pain and inflammation.
  • This class of compounds works by preventing the synthesis of prostaglandins and side-effects such as damage to the gastic mucosa often appear.
  • it has surprisingly become possible to reduce pain without, sedative effects by the use of at least one isomer of inositoltrisphosphate (IP 3 ) for the preparing of a medicament effective as an analgesic.
  • IP 3 inositoltrisphosphate
  • the medicament is intended to be used for preventing, alleviating and combatting pain.
  • the medicament can be used for example in the following conditions in order to reduce pain:
  • Tissue damage induced mechanically or chemically such as burns, trauma i.e. wounds or injuries caused by physical damage.
  • Inflammatory conditions such as joint inflammations.
  • the medicament can also be effective in other disorders or conditions where reduction of pain is desirable.
  • the medicament exerts significant analgesic effects without showing any side-effects and without any sedative effects which is very beneficial for the patient.
  • IP IP-techniques
  • the production of IP and the isolation of the different isomers thereof are disclosed in the US patent No 4.777.134.
  • the IP isomers can also be produced by synthetic methods, chemically or enzymatically, starting with e.g. inositol and a phosphorus source.
  • microbiological production methods including hybrid DNA-techniques of IP_ are also suitable.
  • the medicament used according to the invention exists in unit dosage form.
  • Tablets, granules or capsules are suitable administration forms for such unit dosage. Futhermore, tablets and granules can easily be surface treated such as to provide an enteric coating to prevent an uncontrolled hydrolysis in the stomach and to bring about a desired absorption in the intestine.
  • Other suitable administration forms are slow release and trans- dermal administration.
  • a usual pharmaceutically acceptable additive, excipient and/or carrier can be included in the medicament.
  • the tablets or granules can also contain a disintegrant which causes the tablets or the granules, respectively, to disintegrate easily in the intestine.
  • the medicament can also consist as such of IP 3 solely without any additive, excipient or carrier.
  • the medicament can be free of other inositol phosphates, IP , IPTON, IP 4 , IP-- and IPg. Accordingly, the mixture of IP isomers can have a purity of 90-100 % or preferably 95-100 %.
  • the medicament can consist of or comprise one or more specific IP_ isomers, each present in substantially pure form.
  • the different isomers can be isolated from each other in substantially pure form, which means that they have a purity of 80-100 %, such as 82-100 % or 85-100 %, pre ⁇ ferably 90-100 %. Since the isomers can be produced in pure form they can be mixed in any proportion, of course.
  • the medicament can consist of IP , wherein said IP is provided by at least one of IP fi .
  • IP -isomer or isomers used for the preparing of the medicament according to the invention are present in salt form in order not to affect the mineral balance negatively.
  • the salt should preferably consist of a sodium, potassium, calcium, zinc or magnesium salt or a micture of two or more of these salts.
  • the medicament contains a surplus or an extra addition of at least one pharmaceutically acceptable salt of calcium, zinc or magnesium with a mineral acid or organic acid. This is especially valuable for elderly persons who are often deficient in these minerals.
  • the preferred dosage for humans falls within the range of 0.1 to 1000 mg, especially 0.1-200 mg IP /day/kg body weight.
  • the medicament usually contains 0.01-1.5 g, such as 0.05-1.3 g or preferably 0.1-1 g of IP per unit dosage.
  • composition used according to the present invention contains at least one, sometimes two or more of the following substances, which correspond to the essential IP -isomer or isomers mentioned above:
  • X is hydrogen, at least one univalent, divalent or multivalent cation, or a mixture thereof, n is the number of ions, and z is the charge of the respective ion;
  • n ranges between 6 to 1 inclusive and z ranges from 1 to 6 inclusive.
  • n is between 3 to 6 inclusive and z is 3, 2 or 1.
  • D-myo-inositol-1.2.6-trisphosphate is preferred.
  • Other inositol trisphoshate isomers that may be utilized in the present invention as the active IP ingredient in the composition have the structural formula
  • inositol trisphosphate compounds is defined by the structural formula (I) where three of R , R , R , R , R and R are hydroxy1 and the remaining three are phos ⁇ phate and R , R , R , R , R g and R are hydrogen.
  • inositol trisphosphates is defined by the structural formula (I) where three of Rl. , R_ z>, R ⁇ -., R_/, R Q y and
  • R are hydroxyl and the remaining three are phosphate and R 2 , R 4 , R 5 , R 8 , R ⁇ 0 and R ⁇ l are hydrogen.
  • Still another group of inositol trisphosphates is defined by the structural formula (I) where three of R., RJ, R , Ro, RXU and R are hydroxyl and the remaining three are phosphate and R 2' R 4' R 6' R 7' R and R are hydrogen.
  • inositol trisphosphates is defined by the structural formula (I) where three of R , R , R R R and R _ are hydroxyl and the remaining three are phosphate and R , R , R , R ? , R 1Q and R are hydrogen.
  • Still yet another group of inositol trisphosphates is defined by the structural formula (I) where three of R , R 3 , R g , g , R n 9 and R_1._2 are hydroxyl and the remaining three are phosphate and R , R , R 5 , R_, R 1Q and R are hydrogen.
  • inositol trisphosphates is defined by the structural formula (I) where three of R ⁇ R 3 , Ro., R_/, R1.U. and R 1_..2_. are hydroxyl and the remaining three are phosphate and R_, R , R 5 , R restroom, R g and R are hydrogen.
  • inositol trisphosphates is defined by the structural formula (I) where three of R , R , R , R , R and R are hydroxyl and the remaining three are phosphate and R 2 , R , R g , R_, R g and R are hydrogen.
  • R n y and R.i. are hydroxyl and the remaining three are phosphate and R , R , R , R and R are hydrogen.
  • Particular inositol trisphosphate compounds within the con ⁇ templation of the above formula include compounds having the structural formula (I) where
  • R R and R _ are phosphate, R , R 3 and R are hydroxyl and
  • R 2 , R 4 , R g , R 8 , R g and R ⁇ 2 are hydrogen;
  • R and R ⁇ are phosphate, R 3 , R-. and R are hydroxyl and
  • R 2 , R 4 , R 6 , R 8 , R g and R 12 are hydrogen; R , R and R are phosphate, R 5 , R ? and R 1Q are hydroxyl and
  • R, R 4 , R 6 , R 8 , R g and R ⁇ 2 are hydrogen;
  • R. R 5 and R are phosphate, R , R- 0 and R are hydroxyl and R 4 , R 6 , R 8 , R g and R ⁇ 2 are hydrogen;
  • R and R are phosphate, R , R 5 and R are hydroxyl and
  • R, R 4 , Rg, R g , R g and R 12 are hydrogen
  • R, R and R are phosphate, R , R 5 and R parole are hydroxyl and R, R 4 , R g , R , R and R_ 2 are hydrogen;
  • R, R_ and R 6 are phosphate, R , R and R 12 are hydroxyl and R. , R ⁇ , R Q , R 1.0- and R. 11. are hydrogen;
  • R_ and R are phosphate, R , R and R are hydroxyl and
  • R, R 4 , R 5 , R g , R 1Q and R 1 are hydrogen;
  • R. R 5 and R are phosphate, R , R and R are hydroxyl and R 4 , R , R , R and R are hydrogen;
  • R 3 and R are phosphate, R 5 , R g and R are hydroxyl and , R 4 , R , R , R and R are hydrogen;
  • R 3 and R are phosphate, R , R and R are hydroxyl and R 4 , R , R , R and R are hydrogen;
  • R 5 and R are phosphate, R 3 , R and R _ are hydroxyl and
  • R, R , R , R , R and R are hydrogen
  • R 5 and R ⁇ 2 are phosphate
  • R 3 , R g and R 1Q are hydroxyl
  • R. , R fi , R_, R and R are hydrogen; R, R 3 and R are phosphate, Rg, R Q and R g are hydroxyl and
  • R. R 4 , 5 , R ? , R 1Q and R 1 are hydrogen;
  • R, R and R g are phosphate, R , R Q and R are hydroxyl and
  • R, R 4 , R 5 , R , R g and R.. are hydrogen;
  • R_ R 5 and R g are phosphate, R ⁇ , R g and R are hydroxyl and
  • R, R 3 , Rg, R 7 , R 1Q and R are hydrogen
  • R, R 5 and R are phosphate, R , R Q and R are hydroxyl and R-.
  • R 4 , Rg, R y , R g and R ⁇ 2 are hydrogen;
  • R and R are phosphate, R , R Q and R are hydroxyl and
  • R, R 4 , R g , R_, R g and R _ are hydrogen
  • R 3 and R are phosphate, R , R and R are hydroxyl and R 4 , R 6 , R g , R 10 and R ⁇ 2 are hydrogen;
  • R, R and R are phosphate, R , R and R are hydroxyl and R 4 , R g , R ? , R 10 and R ⁇ are hydrogen;
  • R, R 3 and R are phosphate, R , R and R are hydroxyl and
  • R, R 4 , R g , R ? , R 1Q and R 1 are hydrogen;
  • R. R 5 and R are phosphate, R , R_ and R are hydroxyl and R 4 , Rg, R ⁇ , R 1Q and R ⁇ are hydrogen;
  • R 5 and R g are phosphate, R 3 , R g and R ⁇ 2 are hydroxyl and R 4 , R g , R ? , R and R are hydrogen; R , R 5 and R are phosphate, R 3 , R g and R g are hydroxyl and
  • R 4 , Rg, R ⁇ , R 1Q and are hydrogen
  • R, X and R g are phosphate, R 5 , R g and R 2 are hydroxyl and
  • R 4 , Rg, R ? , R 1(J and R 1 are hydrogen;
  • R, R 5 and R g are phosphate, R ⁇ , R g and R 2 are hydroxyl and R, R 4 , Rg, R ? , R 10 and R l ⁇ are hydrogen;
  • R, R g and R are phosphate, R f R 3 and Rg are hydroxyl and
  • R. R 4 , Rg, R ? , R 1Q and R 1 are hydrogen;
  • R. R and R are phosphate, R , R 5 and R are hydroxyl and
  • R, R 4 , R g , R ? , R 10 and R.. are hydrogen;
  • R 0 8 and R 12 are phosphate, R , R j . and R Q are hydroxyl and
  • R- R 4 , R g , R ? , R - and R are hydrogen;
  • R E R g and R are phosphate, R , R and R are hydroxyl and R , R , R , R and R ⁇ . are hydrogen;
  • R g and R are phosphate, R 3 , R g and R lake are hydroxyl and R 4 , R g , R 7 , R_ 0 and R . are hydrogen;
  • R and R are phosphate, R , R and R are hydroxyl and R 4 , Rg, R ? , R 10 and R are hydrogen;
  • R g and R g are phosphate, R 1 , R g and R 1 n 2 are hydroxyl and
  • R, R 4 , Rg, R 7 , R 1Q and R are hydrogen
  • R g and R_ 2 are phosphate, R , R g and R ⁇ are hydroxyl and
  • R, R 4 , R 6 , R ? , R 1Q and ⁇ 1 are hydrogen;
  • R, R g and R ⁇ 2 are phosphate, R ⁇ , R g and R g are hydroxyl and
  • R_, R 4 , R g , R ? , R ⁇ o and R-. are hydrogen
  • R 8 , R and R 12 are phosphate, R. ⁇ R 3 and R g are hydroxyl and R 2 , R 4 , Rg, R ? , R 1Q and R 1 are hydrogen.
  • inositol trisphosphate where the inositol is selected from the group myoinositol, cisinositol, epiinositol, alloinositol, neo- inositol, mucoinositol, chiroinositol and scylloinositol.
  • Example 1-3 demonstrate the effect of IP to reduce pain in different conditions and where Example 4 shows the manufacturing of a solution of IP for intravenous administration.
  • the three patients treated with penta- barbital had a pain index of 35 which is in full agreement with data from many other patients treated in a similar way.
  • the three patients treated with IP had a pain index of 15 for the same period which demonstrates that IP very effectively reduces pain. Futhermore no side-effects or sedative effects could be observed during or after the IP 3 -treatment.
  • a total of six patients with rheumatoid arthritis were given an infusion of D-myo-inositol-1.2.6-trisphosphate (IP 3 ) for 48 hours (2 mg/kg/hr) .
  • the pain experienced by each patient was assessed with a pain score ranging from 0 to 10 where a high figure represents a high sense of pain.
  • the average value was 8.4 ⁇ 0.8 before the start of the infusion and after 24 hrs the value was determined to 2.8 ⁇ 0.9. This lower value remained not only during the infusion but also for another twelve days after the infusion was stopped.
  • results show a quick on-set of the reduction of pain and also a long duration of the analgetic properties after the termination of the administration of the compound.
  • IP 3 D-myo-inositol-1.2.6- trisphosphate
  • the control group was given an intravenous dose of saline while the other group was given a dose of 5 mg/kg of the sodium salt of IP 3 -
  • each rat received an intraperitoneal in ⁇ jection of 1 ml of a 1 % (w/w) solution of acetic acid.
  • each animal was placed into in ⁇ dividual observation chambers and the numbers of writhes elicited during the subsequent 25-minute period were recorded. After the observation period the animals were killed by cervical dislocation. The number of writhes during the observation period is an expression of the pain experienced by the animal.
  • the control group had an average of 48 writhes during the period while the group receiving IP had an average of 18 writhes during the period.
  • IP D-myo-inositol-1.2.6-trisphosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93924853A 1992-11-05 1993-10-26 The use of inositoltrisphosphate for the preparation of medicaments Withdrawn EP0666748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9203296 1992-11-05
SE9203296A SE470511B (sv) 1992-11-05 1992-11-05 Användning av inositolreisfosfat för beredning av läkemedel
PCT/SE1993/000872 WO1994009790A1 (en) 1992-11-05 1993-10-26 The use of inositoltrisphosphate for the preparation of medicaments

Publications (1)

Publication Number Publication Date
EP0666748A1 true EP0666748A1 (en) 1995-08-16

Family

ID=20387710

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93924853A Withdrawn EP0666748A1 (en) 1992-11-05 1993-10-26 The use of inositoltrisphosphate for the preparation of medicaments

Country Status (6)

Country Link
EP (1) EP0666748A1 (sv)
JP (1) JPH08503454A (sv)
KR (1) KR950703973A (sv)
AU (1) AU5435994A (sv)
SE (1) SE470511B (sv)
WO (1) WO1994009790A1 (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602463D0 (sv) * 1996-06-24 1996-06-24 Perstorp Ab The use of growth factor modulating compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9409790A1 *

Also Published As

Publication number Publication date
SE470511B (sv) 1994-06-27
WO1994009790A1 (en) 1994-05-11
KR950703973A (ko) 1995-11-17
JPH08503454A (ja) 1996-04-16
SE9203296D0 (sv) 1992-11-05
AU5435994A (en) 1994-05-24
SE9203296L (sv) 1994-05-06

Similar Documents

Publication Publication Date Title
EP0536269B1 (en) The use of inositoltrisphosphate for the preparing of medicaments
US4066678A (en) 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof
US4221784A (en) Process and composition for treating disorders by administering lecithin
WO1996039151A1 (en) Bisphosphonates prevent bone loss associated with immunosuppressive therapy
JP2859318B2 (ja) イノシトールトリホスフェートを含有する骨疾患に対する医薬
CA1174602A (en) Pharmaceutical composition for the treatment of osteopathias
US5407924A (en) Method of treating pain using inositol triphosphate
EP0600834A1 (en) Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
JPH09505581A (ja) イノシトール三燐酸エステルの炎症性障害治療への使用
MX2007001348A (es) Composiciones de vitamina b12.
JPH0133082B2 (sv)
KR20060124619A (ko) 연장된 진정을 위해 프로포폴의 수용성 프로드럭을투여하는 방법
EP0001924B2 (en) Pharmaceutical composition for administering choline
GB2168975A (en) Amides and compositions thereof having anti-inflammatory and analgesic activity
EP0666748A1 (en) The use of inositoltrisphosphate for the preparation of medicaments
CA2112195A1 (en) Preventive and therapeutic agent for arteriosclerosis
JP2001508769A (ja) アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物
EP1399157A1 (en) Combination comprising a p-gp inhibitor and an anti-epileptic drug
WO1999021561A1 (en) Method for treatment of disorders of attention
GB2189703A (en) Vinpocetine
EP0347927A2 (de) Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on (Ebselen) zur Herstellung von Arzneimitteln zur Behandlung von Malaria
US6784194B2 (en) Therapeutic use of a thienylcyclohexylamine derivative
JPH09506603A (ja) 多発性硬化症治療でのペントキシフィリンの使用
WO2001019359A2 (en) Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
WO2005074944A1 (en) Use of sodium neridronate to promote new bone formation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19981102

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990615